Cannabis Risks and Medical Benefits: What the Evidence Actually Shows
An expert narrative review synthesizes seven years of research on recreational harms and medicinal cannabinoid efficacy, finding real but narrow medical benefits alongside well-documented risks from chronic high-THC use, particularly among adolescents and young adults.
Why This Matters
Cannabis legalization is expanding rapidly across jurisdictions, and patient inquiries about both recreational safety and medicinal use are rising in parallel. Clinicians need a credible, current synthesis that distinguishes what the evidence actually supports from what popular discourse assumes. This review arrives at a critical moment: THC potency in commercial products has increased substantially over the past decade, adolescent exposure patterns are shifting, and medicinal cannabinoid prescribing lacks consensus guidelines for most proposed indications. The gap between public perception and scientific evidence remains wide on both the risk and benefit sides.
Clinical Summary
Cannabis research has matured considerably over the past decade, yet the evidence base remains uneven, with strong observational data on some harms and only modest trial evidence for most medicinal claims. This invited narrative review, authored by Wayne Hall, Sven Stockings, Louisa Degenhardt, and colleagues and published in European Archives of Psychiatry and Clinical Neuroscience in 2024, synthesizes findings from systematic reviews, meta-analyses, and selected primary studies identified through PubMed and Cochrane databases over a seven-year search window (2016 to 2023). The review covers the full arc from acute intoxication through chronic recreational harms to medicinal cannabinoid efficacy, grounding its causal reasoning in an explicit four-criterion framework that evaluates strength of association, reverse causation, confounding control, and biological plausibility.
Key findings include odds ratios of 1.25 to 1.97 for traffic accidents following acute cannabis use, a roughly 10 percent lifetime risk of cannabis use disorder among users, dose-dependent associations between chronic use and psychosis risk, and an estimated IQ decline of approximately 2 points per year following onset of frequent or dependent use. Cognitive impairments appear substantially reversible with sustained abstinence, though verbal memory, impulsivity, and executive function may show more persistent deficits. On the medicinal side, the authors report small-to-modest benefits for chronic pain, spasticity, chemotherapy-induced nausea and vomiting, and CBD for refractory epilepsy, while evidence for mental health indications remains inconclusive. The primary limitations include the selective, non-registered search methodology, absence of formal risk-of-bias grading, residual confounding in the observational literature, and an incomplete extracted text that prevents full assessment of all sections. The authors emphasize that most causal claims require further longitudinal and interventional confirmation.
Dr. Caplan’s Take
This review does something genuinely useful: it lays out, in one place, what we can and cannot say about cannabis risks and benefits based on the best available secondary evidence. What it gets right is the honest framing. The authors do not oversell medicinal cannabinoids, and they do not catastrophize recreational use beyond what the data support. But the gap between this kind of expert synthesis and what I can tell a patient sitting across from me remains substantial. When someone asks whether cannabis will help their anxiety, or whether their teenager’s daily use is dangerous, the honest answer is more qualified than most people want to hear. This review confirms that honest complexity.
In practice, I use reviews like this to anchor conversations. For patients with chronic pain who have exhausted first-line options, I discuss the small-to-modest analgesic benefit and the real side-effect profile. For parents concerned about adolescent use, I emphasize the consistent signal around cognitive effects and psychosis risk while being transparent that residual confounding clouds definitive causal claims. I do not recommend cannabinoids for depression, anxiety, or PTSD outside of structured clinical trials. The evidence simply is not there yet, and saying so is part of responsible care.
Clinical Perspective
This review sits at a useful but intermediate position in the research arc. It confirms the broad consensus that chronic high-THC cannabis use carries meaningful risks, particularly for adolescents and individuals with psychosis vulnerability, while reinforcing that medicinal cannabinoid efficacy is real but limited to a narrow set of indications. It does not resolve the central causal uncertainty in the recreational harm literature, where residual confounding and shared liability models remain plausible alternative explanations for many observed associations. Clinicians should not use this review to make definitive causal statements to patients, but they can use it to frame evidence-informed risk discussions, especially around dose, potency, and age of onset.
From a pharmacological standpoint, clinicians prescribing or advising on cannabinoids should be aware of CBD’s inhibition of CYP3A4 and CYP2C19, which can elevate plasma levels of clobazam, warfarin, and certain antiepileptic drugs. THC-containing products carry additive sedation risk when combined with benzodiazepines, opioids, or alcohol. Hepatotoxicity monitoring is warranted with high-dose CBD, particularly in patients on valproate. One concrete, actionable step: when patients report current cannabis use, systematically document frequency, route of administration, THC-to-CBD ratio, and age of onset. This information directly informs individualized risk stratification and supports more precise clinical guidance.
Study at a Glance
- Study Type
- Invited narrative review with selective literature search
- Population
- General adult cannabis users, adolescents and young adults, medical cannabis patients
- Intervention
- Recreational THC/cannabis use; medicinal cannabinoids (herbal, extracted, and synthetic formulations)
- Comparator
- Non-users or placebo, as reported in underlying systematic reviews and meta-analyses
- Primary Outcomes
- Cannabis use disorder, psychosis, cognitive impairment, mood and anxiety disorders, suicidal behavior, traffic accidents, respiratory and cardiovascular harms; analgesic, antiemetic, antispastic, and antiepileptic efficacy
- Sample Size
- Not applicable (synthesis of existing reviews and meta-analyses)
- Journal
- European Archives of Psychiatry and Clinical Neuroscience
- Year
- 2024
- DOI or PMID
- Not provided in available extracted text
- Funding Source
- Originally commissioned by the German Federal Ministry of Health; current update funding not specified
What Kind of Evidence Is This
This is an invited narrative review drawing on a selective literature search of PubMed and Cochrane databases, explicitly described by the authors as updating a prior systematic review rather than conducting a new one. Narrative reviews occupy a middle tier in the evidence hierarchy, above expert opinion but below systematic reviews with formal quality grading and pre-registered protocols. The most important inference constraint is that the authors’ selection and weighting of included studies is not transparent or reproducible, meaning that conclusions reflect expert judgment rather than a methodologically auditable synthesis.
How This Fits With the Broader Literature
This review aligns closely with the conclusions of the 2017 National Academies of Sciences, Engineering, and Medicine report on cannabis, which similarly found substantial evidence for associations with psychosis and cannabis use disorder, moderate evidence for traffic accident risk, and limited-to-moderate evidence supporting medicinal cannabinoid efficacy for chronic pain, spasticity, and chemotherapy-induced nausea. It also echoes the 2018 Cochrane review on cannabinoids for chronic neuropathic pain, which found modest benefit with significant tolerability concerns. Where this review adds value is in its integration of more recent data from the 2016 to 2023 window, including updated meta-analyses on cognitive recovery after abstinence and emerging evidence on cardiovascular risks. It does not substantially challenge prior consensus but sharpens and updates the evidentiary picture at a time when policy discussions demand current data.
Common Misreadings
The most likely overinterpretation is treating the associations reported in this review as established causal relationships. The authors themselves apply a structured causal inference framework and repeatedly flag residual confounding, shared genetic liability, and reverse causation as unresolved threats for outcomes such as depression, anxiety, and suicidal behavior. Stating that “cannabis causes psychosis” oversteps the evidence; the correct framing is that chronic, heavy use is consistently associated with elevated psychosis risk in a dose-dependent pattern, with biological plausibility, but that definitive causation remains debated. Similarly, citing this review as evidence that medicinal cannabis “works” for mental health conditions would directly contradict the authors’ explicit conclusion that such evidence is inconclusive.
Bottom Line
This expert synthesis confirms that chronic high-THC cannabis use carries real, dose-dependent health risks, most robustly for cannabis use disorder and psychosis vulnerability, and most consequentially for adolescents. Medicinal cannabinoids offer genuine but modest benefits for a narrow set of conditions. The review does not establish new causal relationships or generate novel data. For clinicians, it serves as a credible, current reference for framing evidence-based conversations with patients, while reinforcing that sweeping claims in either direction exceed what the science supports.
References
- Hall W, Stockings E, Degenhardt L, et al. Recreational and medicinal cannabis use: an updated review of health risks and medical benefits. Invited narrative review. European Archives of Psychiatry and Clinical Neuroscience. 2024.
- National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017. doi:10.17226/24625.
- Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932-1954. doi:10.1097/j.pain.0000000000001293.
- Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin. 2016;42(5):1262-1269. doi:10.1093/schbul/sbw003.
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358.
Have thoughts on this? Share it:
